Could Johnson & Johnson's conditions on 340B drug sales to hospitals involving contract pharmacy be the thunderclap that rouses Congress?

Could J&J’s Decision to Limit 340B Contract Pharmacy Spur Congress to Act?

Yesterday, we broke the news that Johnson & Johnson announced conditions on 340B drug sales to hospitals on a host of pharmacy inventory staples including immunosuppressants, monoclonal antibodies, blood thinners, and treatments for diabetes, cancer, HIV, mental disorders, pulmonary arterial hypertension, and chemotherapy-induced anemia. Federal grantee covered entities are exempt.

J&J is the world’s biggest drug company. Its decision to restrict 340B pricing is significant financially and symbolically. With the federal court fight over 340B contract pharmacy years away from resolution, and the U.S. Health and Human Services Department (HHS) having taken no 340B enforcement action against drug companies since September, J&J’s policy could be a thunderclap that rouses Congress.

J&J is the world’s biggest drug company. Its decision to restrict 340B pricing when hospitals use contract pharmacies could be a thunderclap that rouses Congress.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report